Design Therapeutics, Inc.
NASDAQ:DSGNBiotechnology
+$0.19 today
- Market cap
- $606.42M
- Beta
- 1.66
- P/E (TTM)
- -10.7
- EPS (TTM)
- -$1.13
Volume 0.32M
Average 0.74M
DSGN Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Design Therapeutics, Inc.NASDAQ: DSGN
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $19.93M rose 86569.6% year over year, ahead of the +8746.7% change in trailing-twelve-month financing cash flow. Sequentially, it fell 21.3% from the prior quarter. Over 3 fiscal years it compounded at +378.4% a year.
Context
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +86569.6% holds above the trailing-twelve-month pace of +8746.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 25.74M USD
- Year-over-year change
- +4917.2%
- 4-year CAGR
- -49.0%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25.74M | +4917.2% |
| FY2024 | 2024-12-31 | 513K | -29.1% |
| FY2023 | 2023-12-31 | 724K | +208.1% |
| FY2022 | 2022-12-31 | 235K | -99.9% |
| FY2021 | 2021-12-31 | 379.21M | — |
Financing Cash Flow vs competitors
How DSGN compares with its peers on the latest reported figures
- DSGN's LTM Mar 2026 financing cash flow of $45.65M is the smallest of the 11 companies compared; the peer median is $212.04M.
- Its year-over-year change of +8746.7% is the 3rd highest of 11, against a peer median of +358.3%.
- Over three fiscal years its annual growth of +378.4% compares with a peer median of +27.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $713.47M | +170.6% | +187.7% | — | |
| LTM Jun 2026 | $536M | +2312.8% | +25.4% | 53.1% | |
| LTM Mar 2026 | $489.54M | +101.0% | +93.7% | 681.8% | |
| LTM Sep 2026 | $261.93M | +546.0% | — | 27.3% | |
| LTM Mar 2026 | $243.75M | +18.9% | +37.5% | — | |
| LTM Mar 2026 | $180.57M | -256.8% | — | 8.3% | |
| LTM Mar 2026 | $180.34M | +37.9% | +28.0% | 562.2% | |
| LTM Mar 2026 | $173.2M | +64727.2% | -4.7% | — | |
| LTM Mar 2026 | $168.36M | +15274.9% | +26.0% | — | |
| LTM Mar 2026 | $109.5M | +6044.6% | -1.3% | — | |
| LTM Mar 2026 | $45.65M | +8746.7% | +378.4% | — | |
| Peer median (excluding DSGN) | $212.04M | +358.3% | +27.0% | 53.1% | |
Competitors are the stored peer set for DSGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (35.53M) | (63.31M) | (66.86M) | (49.59M) | (69.79M) |
| Depreciation & Amortization | 129K | 406K | 537K | 596K | (2.63M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.69M | 10.93M | 13.09M | 13.07M | 14.55M |
| Change in Working Capital | 1.4M | 1.99M | 728K | (993K) | 3.11M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.41M | 5.39M | (1.25M) | (1.22M) | 4.49M |
| Other Working Capital | (1.02M) | (3.39M) | 1.97M | 226K | (1.38M) |
| Other Non-Cash Items | (58K) | (1.33M) | (6.05M) | (6.19M) | 406K |
| Operating Cash Flow | (29.38M) | (51.32M) | (58.56M) | (43.11M) | (54.36M) |
| Capital Expenditures | (1.54M) | (918K) | (256K) | (340K) | (193K) |
| Acquisitions (Net) | 52.11K | 39K | 0 | 0 | 0 |
| Purchases of Investments | (86.26M) | (313M) | (224.7M) | (230.18M) | (291.78M) |
| Sales of Investments | 34.16M | 92.89M | 277.5M | 274.47M | 314.89M |
| Other Investing Activities | (52.11K) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (53.64M) | (220.99M) | 52.54M | 43.96M | 22.91M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 254.27M | 662K | 724K | 513K | 25.74M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 228K | (427K) | 0 | 0 | 0 |
| Financing Cash Flow | 379.21M | 235K | 724K | 513K | 25.74M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 296.19M | (272.07M) | (5.3M) | 1.36M | (5.71M) |
| Free Cash Flow | (30.92M) | (52.24M) | (58.82M) | (43.45M) | (54.55M) |
Design Therapeutics, Inc.
NASDAQ:DSGN
Intrinsic Alpha fair value
Locked
Current Price
$9.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.